Join the Varenicline group to help and get support from people like you.
Varenicline News
The 3 Best Ways to Stop Smoking, Rated by Science
THURSDAY, Sept. 5, 2024 – Thinking about quitting smoking? There are three top ways to help you stop, a new review finds. According to the study, folks wanting to quit should turn to: Varenicline,...
Varenicline, Nicotine-Containing E-Cigarettes Help in Quitting Smoking
WEDNESDAY, June 19, 2024 – Varenicline and nicotine-containing electronic cigarettes (ECs) are both effective in helping individuals in quitting smoking conventional cigarettes, according to a study...
Quit-Smoking Drug Chantix May Also Help Folks Stop Vaping
TUESDAY, May 21, 2024 – A quit-smoking drug appears to help people drop their vaping addiction, a new study shows. Vapers who took varenicline (Chantix) were significantly more likely to quit using...
Quit-Smoking Meds Not Working for You? Try Upping the Dose
FRIDAY, May 2, 2024 – Folks struggling to quit smoking might need a bump up on the dose of medication they’re using to help them stop, according to new clinical trial results. Patients are more l...
FDA Approves Tyrvaya (varenicline solution) Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease
PRINCETON, N.J., Oct. 18, 2021 /PRNewswire/ – Oyster Point Pharma, Inc. (Nasdaq: OYST), today announced that the U.S. Food and Drug Administration (FDA) has approved Tyrvaya (varenicline solution)...
FDA Medwatch Alert: Pfizer Expands Voluntary Nationwide Recall to include All Lots of Chantix® (Varenicline) Tablets Due to N-Nitroso Varenicline Content
Pfizer is voluntarily recalling all lots of Chantix 0.5 mg and 1 mg Tablets to the patient (consumer/user) level due to the presence of a nitrosamine, N-nitroso-varenicline, at or above the FDA...
FDA Medwatch Alert: Pfizer Expands Voluntary Nationwide Recall to include Four Additional Lots of Chantix (varenicline) Tablets Due to N- Nitroso Varenicline Content
August 16, 2021 – Pfizer is voluntarily recalling an additional four lots of Chantix 0.5mg/1 mg Tablets to the patient (consumer/user) level due to the presence of a nitrosamine,...
FDA Medwatch Alert: Pfizer Issues a Voluntary Nationwide Recall for Twelve Lots of Chantix (Varenicline) Tablets Due to N-Nitroso Varenicline Content
July 19, 2021 – Pfizer is voluntarily recalling two lots of Chantix 0.5mg Tablets, two lots of Chantix 1 mg Tablets, and eight lots of a Chantix kit of 0.5mg/1 mg Tablets to the patient...
FDA Medwatch Alert: FDA Alerts Health Care Professionals and Patients to a Voluntary Recall of Chantix (varenicline) to the Warehouse Level
[7/02/2021] FDA is alerting patients and health care professionals to Pfizer’s voluntary recall of nine lots of the smoking cessation drug, varenicline (brand name Chantix), to the warehouse level. T...
FDA Medwatch Alert: Chantix (varenicline) and Zyban (bupropion): Drug Safety Communication - Mental Health Side Effects Revised
ISSUE: Based on an FDA review of a large clinical trial that FDA required the drug companies to conduct, FDA determined the risk of serious side effects on mood, behavior, or thinking with the...
FDA Medwatch Alert: Chantix (Varenicline): Safety Communication - Updated Safety Review On The Risk of Cardiovascular Adverse Events
ISSUE: FDA is informing the public about the results of a large, combined analysis (called a meta-analysis) of clinical trials that compared patients who received the smoking cessation drug Chantix...
FDA Medwatch Alert: Chantix (varenicline)
Audience: Healthcare professionals, consumers [UPDATE 10/24/2011] FDA has reviewed the results from two FDA-sponsored epidemiological studies that evaluated the risk of neuropsychiatric adverse...
FDA Medwatch Alert: Chantix (varenicline): Label Change - Risk of Certain Cardiovascular Adverse Events
[UPDATED 07/22/2011] FDA has approved an updated drug label for Chantix (varenicline) to include information about the efficacy and safety of the drug in two patient populations who may benefit...
Further information
Related condition support groups
Smoking Cessation, Keratoconjunctivitis Sicca